- Home
- AIO vs NBTX Comparison
AIO vs NBTX Comparison
Compare AIO & NBTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AIO
- NBTX
- Stock Information
- Founded
- AIO 2019
- NBTX 2003
- Country
- AIO United States
- NBTX France
- Employees
- AIO N/A
- NBTX N/A
- Industry
- AIO Finance/Investors Services
- NBTX Biotechnology: Pharmaceutical Preparations
- Sector
- AIO Finance
- NBTX Health Care
- Exchange
- AIO Nasdaq
- NBTX Nasdaq
- Market Cap
- AIO 808.3M
- NBTX 868.8M
- IPO Year
- AIO N/A
- NBTX 2020
- Fundamental
- Price
- AIO $24.13
- NBTX $27.79
- Analyst Decision
- AIO
- NBTX Strong Buy
- Analyst Count
- AIO 0
- NBTX 1
- Target Price
- AIO N/A
- NBTX $8.00
- AVG Volume (30 Days)
- AIO 141.5K
- NBTX 143.9K
- Earning Date
- AIO 01-01-0001
- NBTX 09-30-2025
- Dividend Yield
- AIO 9.05%
- NBTX N/A
- EPS Growth
- AIO N/A
- NBTX N/A
- EPS
- AIO N/A
- NBTX N/A
- Revenue
- AIO N/A
- NBTX $11,930,711.00
- Revenue This Year
- AIO N/A
- NBTX N/A
- Revenue Next Year
- AIO N/A
- NBTX $114.97
- P/E Ratio
- AIO N/A
- NBTX N/A
- Revenue Growth
- AIO N/A
- NBTX N/A
- 52 Week Low
- AIO $15.09
- NBTX $2.76
- 52 Week High
- AIO $20.25
- NBTX $30.35
- Technical
- Relative Strength Index (RSI)
- AIO 49.20
- NBTX 66.97
- Support Level
- AIO $23.37
- NBTX $23.31
- Resistance Level
- AIO $24.27
- NBTX $29.72
- Average True Range (ATR)
- AIO 0.42
- NBTX 2.19
- MACD
- AIO -0.03
- NBTX 0.69
- Stochastic Oscillator
- AIO 59.89
- NBTX 83.16
About AIO Virtus Artificial Intelligence & Technology Opportunities Fund of Beneficial Interest
Virtus Artificial Intelligence & Technology Opportunities Fund is a diversified, limited-term, closed-end management investment company. The fund's investment objective is to provide total return through a combination of current income, current gains, and long-term capital appreciation.
About NBTX Nanobiotix S.A.
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.